Colović M D, Janković G M, Nikolov V S, Suvajdzić N D, Miletić V D
Institute of Haematology, University Clinical Center Belgrade, Yugoslavia.
Haematologia (Budap). 1994;26(2):91-6.
Within a period from March 1983 to November 1988, 93 newly diagnosed patients with multiple myeloma, 47 men and 46 women aged from 41 to 80 years were treated with protocol VBCMP-M2. A response was achieved in 30 (60%) patients in stage II and 22 (51%) in stage III, the overall response rate being 56%. 41% of all patients entered plateau phase, more frequently in stage II (46%) than in stage III (37%) patients. The median survival of all patients was 35 months. Comparing these groups of patients with other series from the literature, we were not able to demonstrate any advantage of this multidrug combination over other combinations or even melphalan and prednisone alone.
在1983年3月至1988年11月期间，93例新诊断的多发性骨髓瘤患者（47例男性，46例女性，年龄41至80岁）接受了VBCMP - M2方案治疗。Ⅱ期患者中有30例（60%）获得缓解，Ⅲ期患者中有22例（51%）获得缓解，总缓解率为56%。所有患者中有41%进入平台期，Ⅱ期患者（46%）比Ⅲ期患者（37%）更频繁进入该阶段。所有患者的中位生存期为35个月。将这些患者组与文献中的其他系列进行比较，我们无法证明这种多药联合方案比其他联合方案甚至单独使用美法仑和泼尼松有任何优势。
